NEW YORK – BioMérieux announced Monday that it will acquire Norwegian point-of-care diagnostics maker SpinChip Diagnostics for €138 million ($140.8 million).
BioMérieux made a minority investment in SpinChip in March to support its assays for myocardial infarction. As it already owns 20 percent of the Oslo-based firm, the cash-out amount will be approximately €111 million, BioMérieux said in a statement.
SpinChip has developed a diagnostic platform that uses a spinning-disk format and a small benchtop analyzer to perform 10-minute testing from whole-blood samples.
"The SpinChip solution is a game changer, combining the best of both worlds: the ease of use and fast time-to-result of POC systems with the precision and performance of high-sensitivity lab assays. Allowing physicians to make an accurate and rapid diagnosis is crucial for patients with myocardial infarctions," Charles Cooper, executive VP and chief medical officer at BioMérieux, said in a statement.
SpinChip will first focus on cardiac markers such as high-sensitivity troponin I, N-terminal pro-B-type natriuretic peptide, and D-Dimer, and it will expand testing to other clinical areas important in acute care settings, BioMérieux said.
"Having collaborated closely with BioMérieux over the last nine months, we are close to fulfilling our mission to be a contributor to better and more efficient diagnoses," said SpinChip CEO Morten Jurs.
"We already serve the point-of-care market with BioFire SpotFire," said BioMérieux CEO Pierre Boulud. "With SpinChip's disruptive technology, we will complement our offer and strengthen our presence in the point-of-care segment" Boulud added, noting that the acquisition will allow SpinChip to leverage BioMérieux's immunoassay R&D and manufacturing capabilities.
SpinChip expects to apply for CE marking for its high-sensitivity troponin I assay by the end of 2025, and BioMérieux said that the first SpinChip product launch is expected in 2026.